Home › Compare › CCYNF vs ABBV
CCYNF yields 62.05% · ABBV yields 3.12%● Live data
📍 CCYNF pulled ahead of the other in Year 1
Combined, CCYNF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CCYNF + ABBV for your $10,000?
cyan AG, through its subsidiaries, provides intelligent IT security solutions and telecommunication services in the Americas, Europe, the Middle East, Africa, and the Asia-Pacific. The company operates through two segments, Cybersecurity and BSS/OSS. It provides BSS/OSS services, such as connection to the network operator, billing, management of credit balances, provisioning, etc. to mobile virtual network operators (MVNO) to operate a virtual mobile operator. The company also provides OnNet Security, a network-based solution that enables service providers and carriers to take advantage of existing infrastructure by providing converged security; OnDevice Security, an endpoint-based solution that enables service providers to keep customers' devices safe from cyber-threats, including phishing, fraud, malware, and others; child protection solutions, an application-based security solution for child protection; Clean Pipe Domain Name system solutions that enables service providers and MVNO to filter unwanted data traffic and malicious content directly on their network. The company also provides cyber security solutions for the mobile and fixed line internet providers, MVNO, banks, insurance companies, and financial services providers. cyan AG was founded in 2017 and is headquartered in Munich, Germany.
Full CCYNF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.